PracticeVideosBlogFlashcardsEspañol

Free exam prep

BCOP Board Certified Oncology Pharmacist

Practice QuestionsStudy Guide

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias

Key Takeaways

  • Acute Myeloid Leukemia (AML) induction is biomarker-stratified: fit patients with FLT3 mutations receive 7+3 + midostaurin (RATIFY) or quizartinib (QuANTUM-First); CD33+ favorable/intermediate risk receive 7+3 + gemtuzumab ozogamicin (ALFA-0701); and secondary/therapy-related AML (t-AML/AML-MRC) mandates liposomal cytarabine/daunorubicin (CPX-351).
  • Unfit or older AML patients achieve superior overall survival with Venetoclax + Hypomethylating Agents (azacitidine/decitabine per VIALE-A); clinical pharmacists must enforce mandatory 3-day dose ramp-up with tumor lysis syndrome (TLS) prophylaxis and manage critical CYP3A4 inhibitor dose reductions (75% for strong, 50% for moderate inhibitors).
  • Acute Promyelocytic Leukemia (APL, t(15;17)) low-to-intermediate risk (WBC <= 10,000/mcL) is cured chemotherapy-free with All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO); pharmacists must monitor QTc and electrolytes (target K+ >= 4.0 mEq/L, Mg2+ >= 1.8-2.0 mg/dL) and initiate immediate high-dose dexamethasone (10 mg IV BID) at the first suspicion of differentiation syndrome.
  • Ph-negative Acute Lymphoblastic Leukemia (ALL) relies on pediatric-inspired multi-agent chemotherapy incorporating pegaspargase/calaspargase pegol and mandatory CNS prophylaxis; asparaginase-associated toxicities (pancreatitis, thrombosis, hepatotoxicity, neutralizing hypersensitivity requiring switch to recombinant Erwinia chrysanthemi/Rylaze) demand rigorous clinical surveillance.
  • Relapsed/refractory B-ALL paradigms leverage precision biologics and cellular therapy: blinatumomab (CD19/CD3 BiTE continuous IV infusion with boxed warnings for CRS and ICANS), inotuzumab ozogamicin (CD22 ADC; restrict to <=2-3 cycles prior to HSCT to prevent sinusoidal obstruction syndrome/VOD), and CD19 CAR T-cell therapy.
Last updated: August 2026

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias

Acute leukemias represent clonal hematopoietic stem and progenitor cell neoplasms characterized by rapid proliferation of poorly differentiated, immature blast cells that infiltrate the bone marrow, peripheral blood, and extramedullary tissues. This profound marrow replacement leads to severe pancytopenia, life-threatening infection, bleeding diatheses, and metabolic emergencies.

Over the past decade, the management of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) has shifted from empiric cytotoxic chemotherapy toward precision, biomarker-driven therapeutic algorithms. Board-certified oncology pharmacists must master diagnostic cytogenetics, modern risk-stratification schemas (2022 ELN AML recommendations, WHO 2022 / ICC 2022 classifications), pharmacokinetic-pharmacodynamic optimization, cellular logistics, and complex supportive care interception.

1. Acute Myeloid Leukemia (AML): Biology & Risk Stratification

AML is diagnosed by the presence of >= 20% myeloid blasts in the bone marrow or peripheral blood, or by the presence of disease-defining cytogenetic abnormalities—such as t(8;21)(q22;q22.1) [RUNX1::RUNX1T1], inv(16)(p13.1q22) / t(16;16) [CBFB::MYH11], or t(15;17)(q22;q12) [PML::RARA]—irrespective of the absolute blast percentage.

+-----------------------------------------------------------------------------+
|              2022 EUROPEAN LEUKEMIANET (ELN) AML RISK STRATIFICATION        |
|                                                                             |
|   [FAVORABLE RISK]                                                          |
|   - Core-Binding Factor (CBF) AML: t(8;21)(q22;q22.1) or inv(16) / t(16;16) |
|   - Mutated NPM1 without FLT3-ITD                                           |
|   - In-frame bZIP mutated CEBPA (single or biallelic)                       |
|   * Management: 7+3 + Gemtuzumab ozogamicin -> Consolidation HiDAC x 3-4 c  |
|     (Allogeneic HSCT generally withheld in first complete remission [CR1])  |
|                                                                             |
|   [INTERMEDIATE RISK]                                                       |
|   - Mutated NPM1 WITH FLT3-ITD (high or low allelic ratio)                  |
|   - Wild-type NPM1 with FLT3-ITD                                            |
|   - Cytogenetic abnormalities not classified as favorable or adverse (t(9;11)|
|   * Management: 7+3 + FLT3 TKI (Midostaurin/Quizartinib) -> Allo-HSCT in CR1|
|                                                                             |
|   [ADVERSE RISK]                                                            |
|   - Complex karyotype (>= 3 abnormalities) or Monosomal karyotype           |
|   - -5/5q-, -7/7q-, 17p- / TP53 mutation (high variant allele frequency)    |
|   - Inversion(3) / t(3;3), t(6;9), t(v;11q23.3) [KMT2A-rearranged]          |
|   - Myelodysplasia-related gene mutations: ASXL1, BCOR, EZH2, RUNX1, SF3B1, |
|     SRSF2, STAG2, U2AF1, ZRSR2                                              |
|   * Management: CPX-351 or Clinical Trial -> Urgent Allogeneic HSCT in CR1  |
+-----------------------------------------------------------------------------+

2. AML Frontline Induction & Consolidation in Fit Adults

+-----------------------------------------------------------------------------+
|             FRONTLINE INDUCTION DECISION ALGORITHM IN INTENSIVE AML         |
|                                                                             |
|   DIAGNOSIS OF AML IN CHEMOTHERAPY-FIT ADULT (ECOG 0-2, Normal Organ Fn)    |
|                                   |                                         |
|                   Rapid Molecular & Cytogenetic Testing                     |
|                                   |                                         |
|   +---------------+---------------+---------------+---------------------+   |
|   |               |               |               |                     |   |
|   v               v               v               v                     v   |
| [t-AML / AML-MRC] [FLT3-MUTATED]   [CD33+ / CBF]   [IDH1 / IDH2 MUT]  [OTHER]|
| (Secondary AML)   (ITD or TKD)     (Favorable)     (IDH1 or IDH2)   (Wild-Type)|
|   |               |               |               |                     |   |
|   v (Lancet 2018) v (RATIFY/QuANT) v (ALFA-0701)   v (AGILE / Trial)    v   |
| **CPX-351**       **7+3 + TKI**    **7+3 + GO**    **7+3 + Ivosidenib** **7+3**|
| Liposomal         Midostaurin      Gemtuzumab      (or HMA + Ivos/      Standard|
| Dauno/Cytarabine  50 mg PO BID D8-21 ozogamicin    Enasidenib)          Cytarabine
| 100/44 mg/m2 D1,3,5 or Quizartinib  3 mg/m2 D1,4,7                      + Dauno |
+-----------------------------------------------------------------------------+

Standard Cytotoxic Induction: "7+3" Regimen

  • Cytarabine: 100–200 mg/m2/day continuous IV infusion for 7 consecutive days (Days 1–7).
  • Anthracycline: Daunorubicin 60–90 mg/m2/day IV push/infusion on Days 1, 2, 3 OR Idarubicin 12 mg/m2/day IV on Days 1, 2, 3.
  • Bone Marrow Assessment: Performed between Day 14 and Day 21 post-induction. A hypocellular marrow (<10–20% cellularity) with <5% blasts reflects adequate cytoreduction. If residual blasts (>5%) persist with cellular marrow, a "5+2" re-induction (cytarabine 5 days + anthracycline 2 days) or alternative salvage is indicated.

Molecularly Targeted Additions to 7+3 Induction

  1. FLT3 Inhibitors:
    • Midostaurin (RATIFY Trial): Multi-targeted kinase inhibitor added to 7+3 at 50 mg PO twice daily on Days 8 to 21 of induction and consolidation, followed by 12 months of single-agent maintenance. Demonstrated a statistically significant 22% reduction in mortality (OS HR 0.78, p = 0.009) in both FLT3-ITD and FLT3-TKD AML.
    • Quizartinib (QuANTUM-First Trial): Highly potent, selective second-generation FLT3-ITD inhibitor approved for frontline FLT3-ITD mutated AML. Dose: 35.4 mg PO daily on Days 8 to 21 of induction and consolidation, followed by maintenance up to 36 cycles. Black box warning for QTc prolongation and ventricular arrhythmias (requires baseline and weekly ECGs; hold if QTc > 500 ms).
  2. Gemtuzumab Ozogamicin (GO; ALFA-0701 Trial):
    • Humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antitumor antibiotic N-acetyl gamma-calicheamicin via an acid-labile hydrazone linker.
    • Fractionated Regimen: 3 mg/m2 (capped at 4.5 mg/dose) IV on Days 1, 4, and 7 during induction, and Day 1 of consolidation. Maximizes CD33 re-expression and receptor internalization while blunting peak calicheamicin exposure.
    • Efficacy: Substantial event-free and overall survival benefit in Favorable-risk (CBF) and Intermediate-risk AML (no benefit in adverse cytogenetics).
    • Toxicity Pearl: Boxed warning for Hepatic Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome (VOD/SOS). Strict monitoring of total bilirubin, rapid ascites, right upper quadrant pain, and unexplained weight gain.
  3. CPX-351 (Vyxeos; Lancet 2018):
    • Liposomal formulation encapsulating Cytarabine and Daunorubicin in a fixed, synergistic 5:1 molar ratio (1.0 mg cytarabine per 0.44 mg daunorubicin).
    • Indication: Therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in patients aged >= 60 years (or adult secondary AML).
    • Dosing: Induction: 100 units/m2 (Cytarabine 100 mg/m2 + Daunorubicin 44 mg/m2) IV over 90 minutes on Days 1, 3, and 5.
    • Clinical Pharmacist Pearl: Produces prolonged, profound myelosuppression (median time to neutrophil recovery >=500/mcL is 35–42 days vs 28–30 days with 7+3). Requires extended broad-spectrum antimicrobial prophylaxis (antibacterial, antifungal, antiviral) and delayed bone marrow biopsy timing (Day 21–28).

Consolidation Therapy: High-Dose Cytarabine (HiDAC)

In favorable- and select intermediate-risk patients achieving complete remission (CR), High-Dose Cytarabine (HiDAC) consolidation for 3 to 4 cycles provides curative post-remission therapy:

  • Dose: 1.5 to 3.0 g/m2 IV over 3 hours every 12 hours on Days 1, 3, 5 (total 6 doses/cycle) OR Days 1, 2, 3.
+-----------------------------------------------------------------------------+
|                 CRITICAL PHARMACIST PROTOCOLS FOR HiDAC SAFETY              |
|                                                                             |
|   1. NEUROTOXICITY (CEREBELLAR TOXICITY INTERCEPTION)                       |
|      - Pathophysiology: Cytarabine and its active metabolite ara-CTP cross  |
|        the blood-brain barrier; accumulation induces Purkinje cell necrosis.|
|      - Risk Factors: Advanced age (>60 yr), renal insufficiency (CrCl <50), |
|        prior central nervous system disease, rapid infusion rates (<3 hr).  |
|      - Manifestations: Dysdiadochokinesia (impaired rapid alternating hand  |
|        movements), cerebellar ataxia, dysmetria (finger-to-nose overshoot),  |
|        nystagmus, slurred speech, encephalopathy.                           |
|      - PHARMACY MANDATE: Mandatory baseline and PRE-DOSE neurologic exams   |
|        prior to EVERY HiDAC dose. Discontinue HiDAC IMMEDIATELY upon the    |
|        first sign of cerebellar ataxia (damage may become irreversible!).   |
|      - Renal Dose Adjustment: If CrCl 30-50 mL/min, reduce dose by 50%     |
|        (e.g., 1.0 to 1.5 g/m2 IV Q12H); avoid HiDAC if CrCl < 30 mL/min.    |
|                                                                             |
|   2. CHEMICAL / HEMORRHAGIC CONJUNCTIVITIS PROPHYLAXIS                      |
|      - Pathophysiology: Cytarabine is actively excreted into tear film.     |
|      - PHARMACY MANDATE: Initiate **Prednisolone acetate 1%** (or Dexameth- |
|        asone 0.1%) ophthalmic suspension: **2 drops in each eye QID**       |
|        starting 6-12 hours BEFORE first HiDAC infusion and continuing for   |
|        24 to 48 hours AFTER the final HiDAC dose.                           |
+-----------------------------------------------------------------------------+

3. AML in Unfit Adults: Venetoclax Combinations & Targeted Agents

For patients ineligible for intensive chemotherapy due to age (>=75 years) or severe comorbidities (ECOG >= 2, severe cardiac, pulmonary, or renal impairment), the standard of care is Venetoclax combined with a Hypomethylating Agent (HMA: Azacitidine or Decitabine).

+-----------------------------------------------------------------------------+
|               VIALE-A PROTOCOL: VENETOCLAX + AZACITIDINE                    |
|                                                                             |
|   - **Azacitidine:** 75 mg/m2 SC or IV daily on Days 1 to 7 of 28-day cycle |
|   - **Venetoclax Ramp-Up:** (Daily oral dosing with low-fat food + water):  |
|       * Day 1: 100 mg PO daily                                              |
|       * Day 2: 200 mg PO daily                                              |
|       * Day 3 and beyond: **400 mg PO daily** (Target Full Dose)            |
|   - Key Efficacy (DiNardo et al. NEJM 2020): Median OS **14.7 vs 9.6 mos**  |
|     (HR 0.66, p < 0.001); Composite CR rate **66.4% vs 28.3%** (p < 0.001).  |
+-----------------------------------------------------------------------------+

Pharmacist Management of Venetoclax Drug-Drug Interactions & TLS

  1. CYP3A4 Drug Interactions (CRITICAL BOARD TOPIC):
    • Venetoclax is metabolized extensively by CYP3A4. Concomitant administration with azole antifungals drastically elevates venetoclax AUC:
Concomitant CYP3A4 InhibitorAzole / Drug ExamplesVenetoclax Target Dose (Normally 400 mg daily)
Strong CYP3A4 InhibitorPosaconazole, Voriconazole, Ketoconazole, Clarithromycin, ItraconazoleReduce dose by 75–80% -> 70 mg to 100 mg PO daily
Moderate CYP3A4 InhibitorFluconazole, Isavuconazole, Diltiazem, Verapamil, CiprofloxacinReduce dose by 50% -> 200 mg PO daily
Strong CYP3A4 InducerRifampin, Carbamazepine, Phenytoin, St. John's WortAVOID CO-ADMINISTRATION (reduces venetoclax AUC by >80%)
  1. Tumor Lysis Syndrome (TLS) Prevention & Cytoreduction:
    • Baseline WBC must be < 25,000/mcL prior to initiating venetoclax; utilize Hydroxyurea (1–4 g/day) to cytoreduce peripheral leukocytosis.
    • Ensure vigorous hydration (1.5–2 L/day oral or IV) and uric acid lowering therapy (Allopurinol 300 mg daily or Rasburicase 0.2 mg/kg for high uric acid).

IDH1 and IDH2 Inhibitors in AML

  • Ivosidenib (Tibsovo): Oral small-molecule inhibitor of mutated Isocitrate Dehydrogenase 1 (IDH1 R132). Indicated as monotherapy or combined with Azacitidine (AGILE trial: median OS 24.0 vs 7.9 months; HR 0.44). Dose: 500 mg PO daily. Signature toxicities: Differentiation Syndrome and QTc prolongation (monitor ECG, hold if QTc > 500 ms).
  • Enasidenib (Idhifa): Oral allosteric inhibitor of mutated IDH2 (R140, R172). Dose: 100 mg PO daily. Signature toxicities: Differentiation Syndrome and indirect hyperbilirubinemia (competitively inhibits UGT1A1; benign, non-hepatotoxic unconjugated bilirubin elevation).
  • Olutasidenib (Rezlidhia): Potent IDH1 inhibitor for relapsed/refractory IDH1-mutated AML. Dose: 150 mg PO BID on an empty stomach.
+-----------------------------------------------------------------------------+
|                    DIFFERENTIATION SYNDROME (DS) INTERCEPTION               |
|                                                                             |
|   - Pathophysiology: Rapid terminal differentiation and blast maturation    |
|     triggers massive pro-inflammatory cytokine release (IL-1beta, IL-6, TNF)|
|     and endothelial transmigration.                                         |
|   - Clinical Signs: Unexplained fever, rapid weight gain (>5 kg), dyspnea,  |
|     pleural/pericardial effusions, pulmonary infiltrates, acute renal injury|
|   - PHARMACY INTERVENTION: Initiate **Dexamethasone 10 mg IV every 12 hours**|
|     IMMEDIATELY upon first clinical suspicion. Do NOT delay for imaging!    |
|   - Continue dexamethasone for a minimum of 3 days until full resolution.   |
|   - Withhold IDH inhibitor or Venetoclax if severe hypoxemia/ICU admission. |
+-----------------------------------------------------------------------------+

4. Acute Promyelocytic Leukemia (APL): Chemotherapy-Free Paradigm

Acute Promyelocytic Leukemia (APL; WHO subtype of AML) is cytogenetically defined by the balanced translocation t(15;17)(q22;q12), resulting in the PML::RARA fusion transcript that arrests promyelocyte differentiation at the promyelocyte stage and initiates severe, life-threatening disseminated intravascular coagulation (DIC) and hyperfibrinolysis.

+-----------------------------------------------------------------------------+
|                      APL RISK-DIRECTED FRONTLINE PROTOCOLS                  |
|                                                                             |
|   CONFIRMED OR HIGHLY SUSPECTED APL (Presence of Promyelocytes / Auer Rods) |
|                                   |                                         |
|   * EMERGENCY ACTION: Start **ATRA 45 mg/m2/day** IMMEDIATELY upon suspicion!|
|     Do not await molecular/FISH confirmation to initiate ATRA!              |
|                                   |                                         |
|                   Baseline White Blood Cell (WBC) Count                     |
|                                   |                                         |
|         +-------------------------+-------------------------+               |
|         |                                                   |               |
|         v                                                   v               |
|   [LOW-TO-INTERMEDIATE RISK]                         [HIGH RISK]            |
|   (WBC <= 10,000 / mcL)                              (WBC > 10,000 / mcL)   |
|         |                                                   |               |
|         v (APL0406 Trial: Lo-Coco NEJM)                     v               |
|   **CHEMOTHERAPY-FREE REGIMEN**                      **CYTOREDUCTIVE REGIMEN**|
|   - ATRA: 45 mg/m2/day PO (2 divided doses)          - ATRA + Arsenic       |
|   - ATO: 0.15 mg/kg/day IV daily                       Trioxide (ATO)       |
|   - Duration: Induction until bone marrow CR           PLUS                 |
|   - Consolidation: ATO 0.15 mg/kg/d 5 d/wk x 4 wks   - Idarubicin 12 mg/m2  |
|     Q8W x 4 cycles; ATRA 2 wks on / 2 wks off x 7 c    Days 2, 4, 6, 8 OR   |
|   - 97%+ Complete Remission & OS > 98%!              - Gemtuzumab ozogamicin|
|                                                        6 mg/m2 Day 1        |
+-----------------------------------------------------------------------------+

Critical Pharmacist Monitoring in APL

  1. APL Coagulopathy Management:
    • Medical emergency driven by annexin II overexpression, tissue factor release, and hyperfibrinolysis.
    • Transfuse Cryoprecipitate to maintain Fibrinogen >= 150 mg/dL.
    • Transfuse Platelets to maintain Platelet count >= 30,000–50,000/mcL.
    • Avoid invasive procedures (central venous lines, lumbar punctures) until DIC is corrected.
  2. Arsenic Trioxide (ATO) Cardiac Safety & Electrolyte Gating:
    • ATO induces QTc prolongation, torsades de pointes, and sudden death via potassium channel blockade.
    • Electrolyte Mandate: Enforce strict serum electrolyte thresholds prior to daily ATO infusion:
      • Serum Potassium (K+) >= 4.0 mEq/L (supplement vigorously).
      • Serum Magnesium (Mg2+) >= 1.8–2.0 mg/dL.
    • ECG Gating: Obtain 12-lead ECG weekly. If absolute QTc > 500 ms, hold ATO, re-correct electrolytes to upper normal limits, review concomitant QTc-prolonging drugs (antiemetics, azoles, fluoroquinolones), and resume ATO only when QTc falls below 460 ms.
  3. Pseudotumor Cerebri (Intracranial Hypertension):
    • ATRA can induce severe headache, nausea, papilledema, and elevated intracranial pressure (common in adolescents/young adults). Manage with dose reduction (to 25 mg/m2/day), acetazolamide, and analgesics.

5. Acute Lymphoblastic Leukemia (ALL): Multi-Agent & Targeted Protocols

ALL arises from neoplastic transformation of B-cell (~75–80%) or T-cell (~20–25%) lymphoid precursors. The therapeutic paradigm is structured into four distinct phases: Induction, Consolidation/Intensification, CNS Prophylaxis, and Long-Term Maintenance.

+-----------------------------------------------------------------------------+
|                    ADULT ALL PHARMACOTHERAPY FRAMEWORK                      |
|                                                                             |
|   1. INDUCTION (Goal: Complete Remission + Eradication of Blast Cells)      |
|      - Multi-agent backbone (CALGB 10403, Hyper-CVAD, or GRAALL):           |
|        * Vincristine + Corticosteroid (Dexamethasone or Prednisone)         |
|        * Anthracycline (Daunorubicin / Doxorubicin)                         |
|        * Pegaspargase / Calaspargase pegol (in Ph-negative disease)         |
|        * BCR-ABL1 TKI (Ponatinib / Dasatinib in Ph-positive ALL)            |
|                                                                             |
|   2. CNS PROPHYLAXIS & THERAPY (MANDATORY IN ALL ALL REGIMENS!)             |
|      - Intrathecal (IT) Chemotherapy: Triple IT (Methotrexate 12-15 mg +    |
|        Cytarabine 30-50 mg + Hydrocortisone 15-30 mg) or IT Methotrexate    |
|      - Systemic High-Dose Methotrexate (1-3 g/m2) with Leucovorin Rescue    |
|                                                                             |
|   3. CONSOLIDATION / INTENSIFICATION                                        |
|      - High-Dose MTX, High-Dose Cytarabine, 6-Mercaptopurine, Cyclophosphamide|
|      - Blinatumomab consolidation for MRD-positive OR MRD-negative CR1      |
|                                                                             |
|   4. MAINTENANCE THERAPY (2 to 3 Years Total Duration)                      |
|      - Daily Oral 6-Mercaptopurine (6-MP: 50-75 mg/m2/day)                  |
|      - Weekly Oral Methotrexate (20 mg/m2/week)                             |
|      - Monthly pulses of IV Vincristine + Oral Dexamethasone/Prednisone     |
+-----------------------------------------------------------------------------+

Asparaginase Pharmacology & Toxicity Management

Asparaginase hydrolyzes circulating extracellular L-asparagine into aspartic acid and ammonia. Unlike healthy cells, leukemic lymphoblasts lack asparagine synthetase (ASNS) and cannot synthesize endogenous asparagine, resulting in rapid inhibition of protein synthesis and apoptosis.

+-----------------------------------------------------------------------------+
|                 ASPARAGINASE CLINICAL FORMULATIONS & TOXICITY               |
|                                                                             |
|   [FORMULATIONS]                                                            |
|   - **Pegaspargase (Oncaspar):** Pegylated E. coli L-asparaginase (2,500    |
|     units/m2 IM/IV Q14D). Extended half-life ~5.5-7 days.                   |
|   - **Calaspargase pegol (Asparlas):** Succinimidyl carbonate pegylated     |
|     E. coli asparaginase (2,500 units/m2 Q21D). Extended half-life ~16 days.|
|   - **Rylaze (Recombinant Erwinia chrysanthemi):** Indicated for patients   |
|     who develop Grade >= 2 hypersensitivity or silent inactivation to      |
|     E. coli pegaspargase. Dose: 25 mg/m2 IM/IV every 48 hours or M/W/F.     |
|                                                                             |
|   [SIGNATURE TOXICITIES & INTERVENTIONS]                                    |
|   1. Hypersensitivity / Silent Inactivation: Measure nadir serum asparagi- |
|      nase activity (SAA). If SAA < 0.1 IU/mL, switch to Erwinia / Rylaze.   |
|   2. Acute Pancreatitis (5-10%): Severe epigastric pain + lipase/amylase    |
|      >3x ULN. PERMANENTLY DISCONTINUE asparaginase if clinical pancreatitis.|
|   3. Coagulopathy & Thromboembolism (10%): Depletion of Antithrombin III    |
|      (AT-III), Protein C, and Protein S. Monitor AT-III levels and          |
|      fibrinogen. Administer antithrombin concentrates or enoxaparin.        |
|   4. Hepatotoxicity: Severe steatosis, transaminitis, hyperbilirubinemia.   |
|   5. Hyperglycemia: Inhibits insulin synthesis. Manage with insulin.        |
+-----------------------------------------------------------------------------+

Philadelphia Chromosome-Positive ALL (Ph+ ALL: BCR-ABL1)

  • Ph+ ALL represents ~25–30% of adult ALL (increases to >50% in older adults). Historically associated with dismal outcomes, the incorporation of BCR-ABL1 TKIs into induction and consolidation has revolutionized survival:
  • Preferred Regimens:
    • Hyper-CVAD + Ponatinib: Ponatinib 45 mg daily during Cycle 1, de-escalating to 15–30 mg daily upon achieving complete molecular response (CMR), combined with alternating Hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone) and high-dose MTX/cytarabine (Jabbour et al. Lancet Haematol 2018; 5-year OS >75%).
    • Chemotherapy-Free Frontline (D-ALBA Trial): Dasatinib (140 mg daily) + Blinatumomab induction and consolidation eliminates high-dose anthracyclines/alkylators, achieving high rates of molecular complete response with minimal organ toxicity.

Relapsed / Refractory ALL: Targeted Biologics & Cellular Therapy

+-----------------------------------------------------------------------------+
|            TARGETED BIOLOGICS IN RELAPSED / REFRACTORY B-ALL                |
|                                                                             |
|   [BLINATUMOMAB (Blincyto) - Bispecific T-Cell Engager (BiTE)]              |
|   - Target: CD19 (on B-ALL blasts) + CD3 (on cytotoxic T lymphocytes)       |
|   - Administration: **Continuous IV infusion over 28 days** (dedicated pump)|
|     * Cycle 1: 9 mcg/day on Days 1-7 -> Step up to 28 mcg/day on Days 8-28  |
|     * Subsequent Cycles: 28 mcg/day on Days 1-28 (14 days off between cycles)|
|   - Black Box Warnings: **Cytokine Release Syndrome (CRS)** & **Immune      |
|     Effector Cell-Associated Neurotoxicity Syndrome (ICANS)**.              |
|   - Pharmacist Mandate: Premedicate with Dexamethasone 20 mg IV prior to    |
|     initiation and dose escalation; utilize in-line 0.2-micron filter;      |
|     prime infusion line with dedicated pharmacy solution containing polysor-|
|     bate 80 to prevent drug adherence to IV bag/tubing surfaces.            |
|                                                                             |
|   [INOTUZUMAB OZOGAMICIN (Besponsa) - CD22-Targeted ADC]                    |
|   - Target: CD22 on B-ALL blasts; delivers calicheamicin payload            |
|   - Dosing: Fractionated 0.8 mg/m2 Day 1, 0.5 mg/m2 Days 8, 15 of 21-day c.  |
|   - Efficacy: INO-VATE trial (Kantarjian et al. NEJM 2016): Higher CR (80.7%|
|     vs 29.4%) and prolonged OS vs standard salvage chemotherapy.            |
|   - CRITICAL TOXICITY PEARL: **Sinusoidal Obstruction Syndrome / VOD**      |
|     * Substantially heightened risk following subsequent Allogeneic HSCT.   |
|     * Pharmacist Mandate: Limit inotuzumab exposure to **<= 2 to 3 cycles** |
|       prior to HSCT; avoid dual-alkylator conditioning (e.g., busulfan-     |
|       cyclophosphamide); maintain rigorous fluid and bilirubin monitoring.  |
+-----------------------------------------------------------------------------+

Master Acute Leukemia Comparative Matrix

Leukemia SubtypeHallmark BiomarkerFrontline Standard RegimenSignature Pharmacotherapy ToxicitiesCore Clinical Pharmacist Interventions
AML (Favorable CBF)t(8;21), inv(16), NPM1+ / FLT3-7+3 + Gemtuzumab ozogamicin -> HiDAC x 3–4 cyclesMyelosuppression, Mucositis, VOD/SOS, Cerebellar toxicity, ConjunctivitisPrednisolone eye drops QID for HiDAC; check neuro exams pre-dose; cap GO dose at 4.5 mg.
AML (FLT3-Mutated)FLT3-ITD or FLT3-TKD7+3 + Midostaurin (or Quizartinib for FLT3-ITD)QTc prolongation, Nausea, Neutropenia, Pulmonary toxicityMidostaurin 50 mg BID on D8–21; Quizartinib 35.4 mg daily; serial 12-lead ECGs; maintain K+ >= 4.0, Mg2+ >= 2.0.
AML (Secondary / t-AML)Prior MDS/chemo, MRC cytogeneticsCPX-351 (Vyxeos) (Cytarabine:Daunorubicin 5:1)Prolonged pancytopenia, Sepsis, Cardiotoxicity, BleedingExtended antibacterial/antifungal prophylaxis; delayed D21–28 bone marrow assessment.
AML (Unfit / Elderly)Any (age >=75 or frail)Venetoclax + Azacitidine (VIALE-A)TLS, Neutropenia, CYP3A4 interactions, Nausea3-day ramp-up (100->200->400 mg); 75% dose reduction for strong CYP3A4 inhibitors (posaconazole); TLS labs Q6–8H.
APL (Low/Int Risk)t(15;17) PML::RARA, WBC <=10kATRA + Arsenic Trioxide (ATO)Differentiation Syndrome, QTc prolongation, DIC / bleedingStart ATRA on suspicion; Dexamethasone 10 mg IV BID for DS; maintain K+ >= 4.0, Mg2+ >= 1.8; cryo for fibrinogen <150.
Ph- ALLPre-B or T-ALL, BCR-ABL1 negativeMulti-agent pediatric regimen + PegaspargasePancreatitis, Thrombosis, Hepatotoxicity, HypersensitivityMonitor AT-III/fibrinogen; check nadir SAA; switch to Rylaze for E. coli allergy; triple IT CNS prophylaxis.
Ph+ ALLt(9;22) BCR-ABL1Hyper-CVAD + Ponatinib (or Dasatinib + Blinatumomab)Arterial occlusive events, Pancreatitis, CRS/ICANSDe-escalate ponatinib from 45 mg to 15 mg upon CMR; vascular risk factor optimization.
Test Your Knowledge

A 68-year-old male with newly diagnosed secondary AML arising from prior myelodysplastic syndrome (AML-MRC, adverse risk) is deemed unfit for intensive cytotoxic chemotherapy due to an ECOG performance status of 2 and moderate ischemic cardiomyopathy (LVEF 42%). The medical team plans to initiate azacitidine (75 mg/m2 SC daily on Days 1–7) plus venetoclax. The patient is currently receiving oral posaconazole delayed-release tablets 300 mg daily for antifungal prophylaxis against invasive aspergillosis. Which of the following represents the most appropriate, guideline-recommended venetoclax dose escalation and maintenance strategy for this patient?

A
B
C
D
Test Your Knowledge

A 32-year-old female presents to the emergency department with profound fatigue, gingival bleeding, epistaxis, and widespread petechiae. Peripheral blood smear demonstrates 38% abnormal promyelocytes with abundant Auer rods in bundles (faggot cells). Initial laboratory workup reveals WBC 3.2 x 10^3/mcL, Hemoglobin 7.8 g/dL, Platelets 22 x 10^3/mcL, Prothrombin Time 21.4 seconds, INR 1.9, Fibrinogen 92 mg/dL (low), and D-dimer > 20 mcg/mL. A bone marrow biopsy is urgently performed, and FISH/RT-PCR testing for PML::RARA t(15;17) is sent. Which of the following represents the most urgent, critical clinical pharmacist intervention for this patient?

A
B
C
D
Test Your Knowledge

A 24-year-old male with newly diagnosed Ph-negative B-cell ALL is receiving induction chemoimmunotherapy per a pediatric-inspired regimen (CALGB 10403). On Day 4 of induction, he receives pegaspargase 2,500 units/m2 intramuscularly. On Day 12, the patient presents to the oncology clinic with severe, constant epigastric abdominal pain radiating to his back, accompanied by intractable nausea and vomiting. Laboratory evaluation reveals Serum Amylase 680 U/L (reference 30–110), Serum Lipase 1,240 U/L (reference 10–140), Total Bilirubin 2.8 mg/dL, and Triglycerides 420 mg/dL. Abdominal CT confirms acute interstitial edematous pancreatitis. How should the clinical oncology pharmacist guide the multidisciplinary team regarding the future use of asparaginase therapy in this patient?

A
B
C
D
Test Your Knowledge

A 52-year-old woman with relapsed CD22-positive, CD19-positive B-cell ALL is being evaluated for salvage therapy prior to a planned matched unrelated donor allogeneic hematopoietic stem cell transplantation (allo-HSCT). The hematologist proposes using inotuzumab ozogamicin (an anti-CD22 calicheamicin conjugate). Which of the following clinical pearls regarding inotuzumab ozogamicin is most critical for the oncology pharmacist to intercept during conditioning and transplant planning?

A
B
C
D
Up Next

11.2 Chronic Leukemias & Myeloproliferative Neoplasms

Continue learning